Device Trial Radar · NCT03203733
Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study
Last checked: Nov 19, 2026Latest source record: Nov 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Jun 12, 2017
Primary completion
Dec 6, 2019
Study completion Dec 31, 2019
Sponsor
- Lead sponsor
- Uppsala UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 29, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates, among study patients with lymphoma or myeloma undergoing autologous SCT, whether cooling oral mucosa with a cooling device compared with ice cubes/crushed ice or ice pop succeeds in reducing the degree of oral mucositis (OM) according to the Oral Mucositis Assessment Scale (OMAS) total,degree of OM according to World Health Organisation (WHO), tolerability of either cooling method. The study is also aiming to , patients subjective experience of OM, rating of general quality of life and oral pain, number of days with total parenteral nutrition (TPN), number of hospital days, total dose of opioids, and C reactive protein during time in care. Finally, the study aims to evaluate weight loss, Leukocyte particle concentration, number of days until bone marrow response, S-albumin, and body temperature.
Conditions
- Cryotherapy Effect
Interventions
Cooral™Device
An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
cryotherapyOther
Oral cooling by ice chips or crushed ice or ice pop
Primary outcomes
What the sponsor says the trial is designed to measure.
- OM according to OMAS total during 28 days or until dischargeTime frame: 28 days or until discharge
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Rikshospitalet in Oslo
Oslo, Norway
Linköping University Hospital
Linköping, Sweden
Örebro University Hospital
Örebro, Sweden
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.